Skip to main content
Have a personal or library account? Click to login
Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity Cover

Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity

Radiology and Oncology
Volume 46 (2012): Issue 3 (September 2012)
By: ,  ,   and    
Open Access
|Jun 2012
References

References

  1. Sytkowski JA.Boston:; 2004.
    Open DOISearch in Google Scholar
  2. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin.2004;: 673-86.
    Open DOISearch in Google Scholar
  3. Debeljak N, Sytkowski AJ. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.2008;: 1302-10.
    Open DOISearch in Google Scholar
  4. Lacombe C, Mayeux P. The molecular biology of erythropoietin.1999;: 22-8.
    Open DOISearch in Google Scholar
  5. Sytkowski AJ. The neurobiology of erythropoietin.2011;: 931-7.
    Open DOISearch in Google Scholar
  6. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues.2008;: 39-61.
    Open DOISearch in Google Scholar
  7. Debeljak N, Sytkowski AJ. EpoR.2007. (doi: 10.1038/mp.a000863.01)
    Search in Google Scholar
  8. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin.2008;: 14-31.
    Open DOISearch in Google Scholar
  9. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia.2001;: 243-59.
    Open DOISearch in Google Scholar
  10. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.2005;: 2597-605.
    Open DOISearch in Google Scholar
  11. Velenik V, Oblak I, Kodre V. Managing anemia with epoetin alfa in patients with rectal cancer.2005;: 133-40.
    Search in Google Scholar
  12. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.2003;: 1255-60.
    Open DOISearch in Google Scholar
  13. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly.2003;: 459-60.
    Open DOISearch in Google Scholar
  14. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.2005;: 5960-72.
    Open DOISearch in Google Scholar
  15. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.2009;: 1532-42.
    Open DOISearch in Google Scholar
  16. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.2010;: 301-15.
    Open DOISearch in Google Scholar
  17. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.2009;: 2838-47.
    Open DOISearch in Google Scholar
  18. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.2009;: E62-71.
    Open DOISearch in Google Scholar
  19. Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling and cancer cells.2007;: pe38.
    Open DOISearch in Google Scholar
  20. Fodor J, Major T, Tóth J, Sulyok Z, Polgár C. Comparison of mastectomy with breast-conserving surgery in invasive lobular carcinoma: 15-Year results.2011;: 227-31.
    Open DOISearch in Google Scholar
  21. Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer1 T. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting.2012; 46(3): 213-225.;: 54-9.
    Open DOISearch in Google Scholar
  22. Małecki K, Gliński B, Mucha-Małecka A, Ryś J, Kruczak A, Roszkowski K, et al. Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment.2010;: 87-92.
    Open DOISearch in Google Scholar
  23. Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer.2004;: 334-40.
    Search in Google Scholar
  24. Martin M. Platinum compounds in the treatment of advanced breast cancer.2001;: 190-208.
    Open DOISearch in Google Scholar
  25. Todorovic V, Sersa G, Flisar K, Cemazar M. Enhanced cytotoxicity of bleomycin and cisplatin after electroporation in murine colorectal carcinoma cells.2009;: 264-73.
    Open DOISearch in Google Scholar
  26. Erčulj N, Kovač V, Hmeljak J, Dolžan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.2012;: 961-7.
    Open DOISearch in Google Scholar
  27. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance.2003;: 7265-79.
    Open DOISearch in Google Scholar
  28. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer.2001;: 3561-5.
    Search in Google Scholar
  29. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.2005;: 7721-35.
    Open DOISearch in Google Scholar
  30. Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Ryden L, Landberg G, et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.2009;: 5552-9.
    Open DOISearch in Google Scholar
  31. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin.2004;: 1525-32.
    Open DOISearch in Google Scholar
  32. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo.2011
    Open DOISearch in Google Scholar
  33. Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway.2007;: 1944-50.
    Open DOISearch in Google Scholar
  34. Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, et al. Recombinant erythropoietin differently af fects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.2008;: 893-901.
    Open DOISearch in Google Scholar
  35. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, et al. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.2010;: 615-26.
    Open DOISearch in Google Scholar
  36. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.2000;: 5988-94.
    Search in Google Scholar
  37. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.2002;: RESEARCH0034.
    Open DOISearch in Google Scholar
  38. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.2009;: 611-22.
    Open DOISearch in Google Scholar
  39. Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation.2009;: 1517-27.
    Open DOISearch in Google Scholar
  40. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ.2004;: 36-42.
    Search in Google Scholar
  41. Smyth GK. Limma: linear models for microarray data. In: Robert Gentleman VJC, Wolfgang Huber, Rafael A. Irizarry, Sandrine Dudoit editor.New York: Springer; 2005. p. 397-420.
    Open DOISearch in Google Scholar
  42. (2008) RDCT.Vienna: R Fundation for Statistical Computing; 2011.
    Search in Google Scholar
  43. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing.1995;: 289-300.
    Open DOISearch in Google Scholar
  44. Zager V, Cemazar M, Hreljac I, Lah TT, Sersa G, Filipic M. Development of human cell biosensor system for genotoxicity detection based on DNA damage-induced gene expression.2010;: 42-51.
    Open DOISearch in Google Scholar
  45. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.1999;: 3077-83.
    Search in Google Scholar
  46. Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, et al. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression.2001;: 151-63.
    Open DOISearch in Google Scholar
  47. Lu CH, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth.2005;: 6516-24.
    Open DOISearch in Google Scholar
  48. Perkins ND. Achieving transcriptional specificity with NF-kappa B.1997;: 1433-48.
    Open DOISearch in Google Scholar
  49. Patel HR, Sytkowski AJ. Erythropoietin activation of AP1 (Fos/Jun).1995;: 619-25.
    Search in Google Scholar
  50. Mariggio S, Bavec A, Natale E, Zizza P, Salmona M, Corda D, et al. Galpha13 mediates activation of the cytosolic phospholipase A2alpha through fine regulation of ERK phosphorylation.2006;: 2200-8.
    Open DOISearch in Google Scholar
  51. Schnellmann RG, Zhuang SG. A death-promoting role for extracellular signal-regulated kinase.2006;: 991-7.
    Open DOISearch in Google Scholar
  52. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy.2008;: 159-85.
    Open DOISearch in Google Scholar
  53. Gewirtz DA, Di X, Walker TD, Sawyer ST. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.2006;: 2232-8.
    Open DOISearch in Google Scholar
  54. Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model.2004;: 171-9.
    Open DOISearch in Google Scholar
  55. Zhang L, Yu J. PUMA, a potent killer with or without p53.2008;: S71-S83.
    Open DOISearch in Google Scholar
  56. Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Vrekoussis T, et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome.2007;: 2016-23.
    Open DOISearch in Google Scholar
  57. Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E, Kampa M. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.2010;: 135-49.
    Open DOISearch in Google Scholar
  58. Notas G, Kampa M, Pelekanou V, Castanas E. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach.2011
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-012-0037-8 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 213 - 225
Published on: Jun 19, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
breast cancer,
erythropoietin,
cisplatin,
cytotoxicity
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2012 Nina Trost, Peter Juvan, Gregor Sersa, Natasa Debeljak, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 46 (2012): Issue 3 (September 2012)
Previous article
Next article